The Homozygous Leu Variant of the Factor XIII Val34Leu Polymorphism as a Risk Factor for the Manifestation of Thrombotic Microangiopathies

Abstract

The 34 Leu (100T) variant of the factor XIII Val34Leu (G100T-) polymorphism slows down fibrinolysis and has been proposed as a thrombotic risk factor. In this pilot study, we enrolled 40 patients (mean age ± SD = 38 ± 11 years) and 728 controls to assess the role of this genetic variant for the manifestation of thrombotic microangiopathies. From the genotype prevalences, an increased manifestation risk for carriers of the TT genotype (homozygous Leu variant) of the factor XIII Val34Leu (G100T-) polymorphism was calculated (odds ratio [OR] = 2.44; 95% confidence interval [CI] = 0.8-7.6; P = .11). This association was statistically significant for patients with thrombotic thrombocytopenic purpura—hemolytic-uremic syndrome (TTP-HUS) (OR = 6.6; 95% CI = 1.7-25.9; P = .006). Our data suggest a role of the homozygous Leu variant of the factor XIII Val34Leu polymorphism in the manifestation of thrombotic microangiopathies. Decreased fibrinolysis in the presence of this genetic variant provides a plausible explanation for this association.

Keywords

thrombotic microangiopathies factor XIII Val34Leu polymorphism fibrinolysis

References

Moake JL Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.

Franchini M. , Zaffanello M. , Veneri D. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome . Thromb Res. 2006;118:177-184.

Furlan M. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Expert Rev Cardiovasc Ther. 2003;1:243-255.

Blackall DP , Marques MB Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation . Am J Clin Pathol. 2004;121 (suppl):81-88.

George JN , Vesely SK , Terrell DR The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004;41:60-67.

Ariëns RAS , Philippou H. , Nagaswami C. , Weisel JW , Lane DA , Grant PJ The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure . Blood. 2000 ;96:988-995.

Wartiovaara U. , Mikkola H. , Szöke G. , et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII A. Thromb Haemost . 2000;84:595-600.

Corral J. , González-Conejero R. , Iniesta JA , Rivera J. , Martínez C. , Vicente C. The F XIII Val34Leu polymorphism in venous and arterial thromboembolism . Haematologica. 2000;85:293-297.

Muszbek L. , Yee VC , Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94: 271-305.

10.

Board PG Genetic polymorphism of the A subunit of human coagulation factor XIII. Am J Hum Genet. 1979; 31:116-124.

11.

Reiner AP , Frank MB , Schwartz SM , et al. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol . 2002;116:376-382.

12.

Kohler HP , Stickland MH , Ossei-Gerning N. , Carter A. , Mikkola H. , Grant PJ Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 1998 ;79:8-13.

13.

Roldán V. , Corral J. , Marín F. , Rivera J. , Vivente V. Effect of factor XIII Val34Leu polymorphism on thrombolytic therapy in premature myocardial infarction. Thromb Haemost. 2002;88:354-355.

14.

Catto AJ , Kohler HP , Coore J. , Mansfield MW , Stickland MH , Grant PJ Association of a common polymorphism in the factor XIII gene with venous thrombosis . Blood. 1999;93:906-908.

15.

Seligsohn U. , Lubetsky A. Genetic susceptibility to venous thrombosis . N Engl J Med. 2001;344:1222-1231.